Context Therapeutics Inc.
NASDAQ: CNTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin A. Lehr
- Employees
- 15
- Headquarters
- Philadelphia, United States
- IPO year
- 2021
- Market cap
- $52.9M
- Website
- https://www.contexttherapeutics.com
Loading CNTX…
Loading profile data…Frequently asked questions about CNTX
What does Context Therapeutics Inc. (CNTX) do?
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agre...
Where does CNTX trade?
Context Therapeutics Inc. (CNTX) trades on the NASDAQ.
What sector is CNTX in?
Context Therapeutics Inc. (CNTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Context Therapeutics Inc.?
Martin A. Lehr is the chief executive officer of Context Therapeutics Inc. (CNTX).
Where is Context Therapeutics Inc. headquartered?
Context Therapeutics Inc. is headquartered in United States.
Does CNTX pay a dividend?
Context Therapeutics Inc. (CNTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CNTX go public?
Context Therapeutics Inc. (CNTX) completed its initial public offering in 2021.